A MULTICENTRE, RANDOMISED, PHASE 3 TRIAL OF A NOVEL, AUTOLOGOUS, THERAPEUTIC VACCINE (VITESPEN) VS. OBSERVATION AS ADJUVANT THERAPY IN PATIENTS AT HIGH RISK OF RECURRENCE AFTER NEPHRECTOMY FOR RENAL CELL CARCINOMA